Both copyright and copyright belong to a class of therapies called GLP-1 GLP-1 agonists . These innovative medicines operate by imitating the body's own substance, Glucagon-like Peptide-1, to assist decrease glucose levels and stimulate a decrease in weight. This similar mechanism of function highlights why these therapies are frequently evaluated

Individuals struggling with obesity are often faced with limited and sometimes ineffective treatment options. However, a groundbreaking new medication, Wegovy, is rapidly changing the landscape of weight loss. Utilized by regulatory bodies for chronic weight management, Semaglutide acts as a glucagon-like peptide-1 (GLP-1) receptor agonist. This p